media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Shining on the top stage! The world’s first three-target agonist DR10624 MASLD/MASH Phase II results were selected for the latest breakthrough abstract of AASLD.

On October 19, 2026, Huadong Medicine Co., Ltd. (hereinafter referred to as “Huadong Medicine”) announced that the results of the Phase II clinical trial (“DR10624-202 Study”) of DR10624, a first-in-class long-acting trispecific agonist independently developed by its holding subsidiary Zhejiang Daer Biotechnology Co., Ltd. (hereinafter referred to as “Daer Biotechnology”) for the treatment of metabolic-associated fatty liver disease (MASLD)/metabolic steatohepatitis (MASH), have been successfully selected as the Late Breaking Abstract (LBA) of The Liver Meeting® (TLM) 2026 of the American Association for the Study of Liver Diseases (AASLD) and will be presented in the form of a Late Breaking Parallel Presentation. The principal investigator of this study, Associate Vice-President (Research) and Professor Mok Hing-yiu of Medicine at the Chinese University of Hong Kong, along with Professor Wong Wai-sun, Assistant Dean (Development) of the Faculty of Medicine and Head of the Department of Gastroenterology and Hepatology, will deliver a presentation on ...
- Source: drugdu
- 172
- October 20, 2026
The world’s first long-acting anti-RSV monoclonal antibody has been commercially launched

Recently, the domestically developed long-acting anti-respiratory syncytial virus (RSV) monoclonal antibody, ritvirabimab injection (trade name: Newdox), was launched in Jinwan District, Zhuhai. This is the world’s first long-acting anti-RSV monoclonal antibody with 9 months of protection data after a single injection, and it was independently developed and produced by Zhuhai TechnoMed Pharmaceutical Co., Ltd. RSV is one of the most common pathogens causing lower respiratory tract infections in infants and young children. The risk of infection increases significantly during the autumn and winter seasons. It is often associated with diseases such as severe pneumonia and bronchiolitis, and poses a particularly prominent threat to premature infants, low birth weight infants, and infants with congenital cardiopulmonary diseases. Source: https://mp.weixin.qq.com/s?__biz=MzIxMjYwMDI5Nw==&mid=2247717580&idx=3&sn=3f2a07c30d243e6b52fc0aeb2869baee&chksm=96e51b57c73949dc987f0a25e6a5421a12bfd06db7332796d4078d21b0d18e20c36f3d42b430&scene=126&sessionid=0#rd
- Source: drugdu
- 99
- October 20, 2026
Lunan Pharmaceutical’s Weikangda® Tegafur Capsules Receive Marketing Approval in Pakistan

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a drug registration certificate for Tegafur Capsules (Viconda®) issued by the Food and Drug Administration of Pakistan (DRAP) , marking that the product has officially obtained market access in Pakistan and can be sold and commercialized there. Tegafur capsules are a compound preparation composed of tegafur, gimeracil, and oteracil potassium. They can inhibit tumor cell proliferation, induce tumor cell apoptosis, enhance the effect of chemotherapy, and reduce the side effects of chemotherapy. They are mainly used to treat patients with unresectable locally advanced or metastatic gastric cancer. During the product’s market approval process in Pakistan, the registration team strictly adhered to local regulations and scientifically and rationally prepared technical documentation, ensuring the product’s successful approval. This provided local gastric cancer patients with a more efficient and accessible treatment option, and laid a solid foundation for subsequent ...
- Source: drugdu
- 113
- October 20, 2026
Announcement Regarding Nimodipine Tablets Passing the Generic Drug Consistency Evaluation

Securities Daily News, October 19th – Xinhua PharmaceuticalThe company announced that it recently received the “Approval Notice for Supplemental Application for Drug” for Nimodipine tablets issued by the National Medical Products Administration. The product has passed the consistency evaluation of generic drug quality and efficacy. The specification is 30mg. This product is used as a continuation treatment after prior use of Nimodipine injection, and can prevent and treat ischemic neurological injury caused by cerebral vasospasm following aneurysmal subarachnoid hemorrhage. It belongs to Category A of the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025)”. Source: https://finance.eastmoney.com/a/202610193900147785.html
- Source: drugdu
- 104
- October 20, 2026
Rosuvastatin Ezetimibe Tablets (I) Receive Registration Approval

Shanghai Securities News (China Securities Network) – Peking University MedicineOn the evening of October 19th, the company announced that it had recently received a Drug Registration Certificate issued by the National Medical Products Administration. Its application for “Rosuvastatin Ezetimibe Tablets (I)” has been reviewed and found to meet the relevant requirements for drug registration, and has been approved for registration. It is understood that the drug is classified as a Class 4 chemical drug, and each tablet contains 10mg of rosuvastatin calcium (calculated as C22H28FN3O6S) and 10mg of ezetimibe. Data shows that rosuvastatin-ezetimibe tablets (I) are a compound preparation composed of rosuvastatin (an HMG-CoA reductase inhibitor) and ezetimibe (a cholesterol absorption inhibitor). Their mechanisms of action are complementary; by inhibiting cholesterol absorption and synthesis, they lower plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), while increasing high-density lipoprotein ...
- Source: drugdu
- 79
- October 20, 2026
北大医药：瑞舒伐他汀依折麦布片(Ⅰ)获注册批件

上证报中国证券网讯北大医药10月19日晚间公告，近日公司收到国家药品监督管理局核准签发的有关《药品注册证书》，其申报的“瑞舒伐他汀依折麦布片(I)” 经审查，符合药品注册的有关要求，批准注册并发给药品注册证书。据悉，该药品注册分类为化学药品4类，规格为每片含瑞舒伐他汀钙10mg(按C22H28FN3O6S计)与依折麦布10mg。资料显示，瑞舒伐他汀依折麦布片(Ⅰ)是由瑞舒伐他汀（HMG-CoA还原酶抑制剂）和依折麦布（胆固醇吸收抑制剂）组成的复方制剂，二者作用机制互补，通过抑制胆固醇的吸收和合成，降低血浆总胆固醇（T-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白B（ApoB）、甘油三酯（TG）和非高密度脂蛋白胆固醇（non-HDL-C）的水平，并能提高高密度脂蛋白胆固醇（HDL-C）水平。其主要用于高胆固醇血症、纯合子型家族性高胆固醇血症（HoFH）的治疗。北大医药表示，上述药物注册批件的获得，进一步丰富了公司现有产品布局，有利于提升公司在慢病领域产品市场的竞争力，对公司未来业绩提升有积极作用。 Source: https://finance.eastmoney.com/a/202610193900214984.html
- Source: drugdu
- 69
- October 20, 2026
Telix teams up with Ekalia (IBA-Framatome JV) to scale up astatine-211 production in the U.S., advancing targeted alpha therapy

On 19 October 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., Euronext) and Framatome, announced a collaboration to advance scalable U.S. production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy (TAT). The collaboration establishes a framework for a dedicated U.S. source of 211At, a scarce, next-generation alpha-emitting isotope whose broader adoption has been constrained by limited production capacity. Under the arrangement, the first IBA alpha-beam cyclotron will be installed and operated at Telix’s RLS Radiopharmacies site in Trevose, near Philadelphia, Pennsylvania. Leveraging Telix’s vertically integrated U.S. manufacturing and distribution platform, the framework provides for the parties to evaluate additional installations across RLS sites as demand for 211At develops. The alliance brings together IBA’s specialized alpha-beam cyclotron technology, Framatome’s nuclear and isotope-production expertise, and Telix’s U.S. radiopharmacy and last-mile infrastructure, clinical portfolio and radiopharmaceutical development capabilities. ...
- Source: drugdu
- 87
- October 19, 2026
Haihe Biopharma’s oral paclitaxel (Bairuisu) approved for breast cancer, the world’s first oral paclitaxel

Shanghai Haihe Biopharma Co., Ltd. announced that its oral paclitaxel solution (brand name: Bairuisu; R&D code: RMX3001/DHP107), co-developed with South Korea’s Dae Hwa Pharmaceutical, has been approved by China’s National Medical Products Administration (NMPA) for a new indication: recurrent or metastatic HER2-negative breast cancer. The product was first approved in September 2024 for advanced gastric cancer patients whose disease progressed during or after first-line fluoropyrimidine-based therapy. 3SBio Inc. (01530.HK) holds the exclusive commercialization rights to the product in Chinese mainland and Hong Kong. In September 2017, Haihe in-licensed the rights to develop, manufacture and sell the product in Chinese mainland, Taiwan, Hong Kong and Thailand from Dae Hwa Pharmaceutical. Paclitaxel is one of the most widely used chemotherapy drugs, with substantial market demand. Until now, all paclitaxel products marketed in China were intravenous formulations that had to be prepared in hospital and given by infusion, requiring frequent hospital visits and ...
- Source: drugdu
- 147
- October 19, 2026
Beijing Fuyuan Pharmaceuticals aims to become the first generic version of a hypertension drug.

Recently, the CDE (Center for Drug Evaluation) website showed that Beijing Fuyuan Pharmaceutical’s esculenta potassium chlorthalidone tablets have had their clinical trial application accepted as a generic Class 3 product. Currently, no company has received approval for marketing or has submitted a production application for esculenta potassium chlorthalidone tablets under review. Mesartan potassium chlorthalidone tablets are a combination antihypertensive drug. Mesartan potassium belongs to the sartan (ARB) class of antihypertensive drugs, which dilates blood vessels and lowers blood pressure by blocking angiotensin receptors. Its antihypertensive effect is relatively strong among drugs of the same class. Chlorthalidone belongs to the thiazide diuretic class, which helps lower blood pressure by promoting sodium and water excretion and reducing blood volume. In recent years, the sales volume of hypertension medications (chemical and biological) has exceeded 60 billion yuan in all six major markets across China’s three major terminals (see the end of this article ...
- Source: drugdu
- 86
- October 19, 2026
The first generic version of Ponatinib from Yuandong Bio has been approved for marketing

On October 15, 2026, according to the official website of the National Medical Products Administration (NMPA ) of China, Ponatinib tablets, submitted by Chengdu ShuoDe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yuandong Bio, were approved for marketing. Public information indicates that this drug is derived from traditional Chinese medicine preparations from medical institutions. Ponatinib tablets are a third-generation BCR-ABL tyrosine kinase inhibitor for leukemia, suitable for patients with chronic myeloid leukemia, acute lymphoblastic leukemia, and other conditions . Chronic myeloid leukemia (CML) is a malignant tumor affecting the blood and bone marrow, accounting for approximately 15% to 20% of adult leukemia cases. According to data released in the “2021 China Chronic Myeloid Leukemia Patient Report White Paper,” 20.2% of the 2,533 patients surveyed were intolerant to drug treatment. Mutations in the BCR-ABL kinase domain are one of the important mechanisms leading to resistance to tyrosine kinase inhibitor (TKI) therapy, ...
- Source: drugdu
- 115
- October 19, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.